ASCO: Targeted Agent Has Slim NSCLC Benefit
CHICAGO (MedPage Today) -- The novel kinase inhibitor nintedanib may slightly delay relapse of non-small cell lung cancer when added to chemotherapy, with perhaps greater benefit in adenocarcinomas, the LUME-Lung 1 trial showed.
Source: MedPage Today Pulmonary - Category: Respiratory Medicine Source Type: news
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Chemotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Respiratory Medicine